Psychedelics Firm MindMed Receives Bullish Rating and Price Target from Canaccord, Initiates NASDAQ Uplisting Canaccord Genuity Released a Comprehensive Research Report on MindMed Complete a with Bullish Buy Rating and Price Target The Leading Psychedelic Drug Development Company Also Submitted an Application to Uplist... read more → September 24, 2020 Ryan T.
